Neurotransmitter antagonism in management of irritable bowel syndrome

被引：6
作者：
Lembo, T [1 ]
机构：
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA
来源：
LANCET | 2000年 / 355卷 / 9209期
关键词：
D O I：
10.1016/S0140-6736(00)02028-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1030 / 1031
页数：2
相关论文
共 4 条
[1]  
Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149
[2]   Functional gut disorders: From motility to sensitivity disorders. A review of current and investigational drugs for their management [J].
De Ponti, F ;
Malagelada, JR .
PHARMACOLOGY & THERAPEUTICS, 1998, 80 (01) :49-88
[3]   Irritable bowel syndrome: A technical review for practice guideline development [J].
Drossman, DA ;
Whitehead, WE ;
Camilleri, M .
GASTROENTEROLOGY, 1997, 112 (06) :2120-2137
[4]   Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron) [J].
Goldberg, PA ;
Kamm, MA ;
SettiCarraro, P ;
vanderSijp, JRM ;
Roth, C .
DIGESTION, 1996, 57 (06) :478-483
1